DB:82P

Stock Analysis Report

Executive Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Pacira BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 82P's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.6%

82P

3.2%

DE Pharmaceuticals

2.2%

DE Market


1 Year Return

-10.6%

82P

-8.2%

DE Pharmaceuticals

-17.2%

DE Market

Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -8.2% over the past year.

Return vs Market: 82P exceeded the German Market which returned -17.2% over the past year.


Shareholder returns

82PIndustryMarket
7 Day8.6%3.2%2.2%
30 Day-23.6%-15.9%-15.7%
90 Day-24.4%-20.0%-24.0%
1 Year-10.6%-10.6%-5.1%-8.2%-14.9%-17.2%
3 Year-28.3%-28.3%19.5%5.9%-16.4%-23.3%
5 Year-61.3%-61.3%13.3%-6.0%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 82P (€30.4) is trading below our estimate of fair value (€122.52)

Significantly Below Fair Value: 82P is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 82P is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 82P is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 82P's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 82P is overvalued based on its PB Ratio (4x) compared to the DE Pharmaceuticals industry average (1.7x).


Next Steps

Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

38.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 82P is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 82P is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 82P's is expected to become profitable in the next 3 years.

Revenue vs Market: 82P's revenue (12% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 82P's revenue (12% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 82P's Return on Equity is forecast to be high in 3 years time (24.7%)


Next Steps

Past Performance

How has Pacira BioSciences performed over the past 5 years?

1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 82P is currently unprofitable.

Growing Profit Margin: 82P is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 82P is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare 82P's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 82P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: 82P has a negative Return on Equity (-3.1%), as it is currently unprofitable.


Next Steps

Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: 82P's short term assets ($408.6M) exceed its short term liabilities ($107.7M).

Long Term Liabilities: 82P's short term assets ($408.6M) exceed its long term liabilities ($368.4M).


Debt to Equity History and Analysis

Debt Level: 82P's debt to equity ratio (86.2%) is considered high.

Reducing Debt: 82P's debt to equity ratio has increased from 60.4% to 86.2% over the past 5 years.


Balance Sheet

Inventory Level: 82P has a high level of physical assets or inventory.

Debt Coverage by Assets: 82P's debt is covered by short term assets (assets are 1.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 82P has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 82P is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 64.7% per year.


Next Steps

Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 82P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 82P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 82P's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 82P's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 82P's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Dave Stack (69yo)

12.42s

Tenure

US$5,835,918

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceutical ...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD5.84M) is above average for companies of similar size in the German market ($USD1.85M).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
David Stack
Chairman & CEO12.42yrsUS$5.84m0.34% $4.4m
Charles Reinhart
Chief Financial Officer3.92yrsUS$1.41m0.0091% $115.9k
Kristen Williams
Chief Administrative Officer & Secretary5.5yrsUS$1.94mno data
Richard Scranton
Consultant1.67yrsUS$2.27m0.038% $488.1k
Dennis McLoughlin
Chief Commercial Officer1.67yrsUS$2.53m0.0067% $85.5k
Max Reinhardt
President0.83yrno datano data
Lauren Riker
Principal Accounting Officer & VP of Finance8.08yrsUS$288.82k0.010% $134.0k
Charles Laranjeira
Chief Technical Officer1.33yrsno data0.0039% $49.2k
Susan Mesco
Head of Investor Relationsno datano datano data
Richard Kahr
Vice President of Human Resources4.75yrsno datano data

3.9yrs

Average Tenure

53yo

Average Age

Experienced Management: 82P's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Stack
Chairman & CEO12.42yrsUS$5.84m0.34% $4.4m
Laura Brege
Independent Director8.83yrsUS$205.42k0.011% $140.6k
Paul Hastings
Lead Director6.83yrsUS$218.42k0.0065% $83.5k
Gary Pace
Independent Director11.83yrsUS$180.22k0.13% $1.7m
Andreas Wicki
Independent Director13.33yrsno datano data
John Longenecker
Independent Director12.75yrsUS$202.42k0.029% $375.7k
Mark Kronenfeld
Independent Director6.83yrsUS$190.42k0.024% $312.3k
Yvonne Greenstreet
Independent Director6.08yrsUS$184.42k0.013% $171.1k
Christopher Christie
Director0.58yrno datano data
Mark Froimson
Independent Director2.83yrsUS$175.42k0.0014% $17.6k

6.8yrs

Average Tenure

60yo

Average Age

Experienced Board: 82P's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 82P insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: 82P
  • Exchange: DB
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.409b
  • Listing Market Cap: US$1.277b
  • Shares outstanding: 42.03m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2011
82PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2011

Biography

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 03:10
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.